Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) FCF Margin (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed FCF Margin for 17 consecutive years, with 1.24% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 602.0% to 1.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.9% through Dec 2025, down 345.0% year-over-year, with the annual reading at 1.9% for FY2025, 345.0% down from the prior year.
  • FCF Margin hit 1.24% in Q4 2025 for Integra Lifesciences Holdings, down from 6.4% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 21.71% in Q2 2021 to a low of 10.5% in Q1 2025.
  • Historically, FCF Margin has averaged 7.1% across 5 years, with a median of 5.59% in 2024.
  • Biggest five-year swings in FCF Margin: surged 1612bps in 2021 and later tumbled -1178bps in 2023.
  • Year by year, FCF Margin stood at 10.32% in 2021, then skyrocketed by 73bps to 17.81% in 2022, then crashed by -52bps to 8.62% in 2023, then plummeted by -45bps to 4.78% in 2024, then plummeted by -126bps to 1.24% in 2025.
  • Business Quant data shows FCF Margin for IART at 1.24% in Q4 2025, 6.4% in Q3 2025, and 2.7% in Q2 2025.